Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Pseudomonas aeruginosa Meningitis-Reference-Cited by-同舟云学术

Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Pseudomonas aeruginosa Meningitis

Published:2020-11-12 Issue:12 Volume:7 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

McCreary Erin K¹^ORCID,Byers Karin E¹,Fernandes Carolyn¹,Kline Ellen G¹,Nicolau David P²,Shields Ryan K¹

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

2. Center for Anti-Infective Research and Development, Hartford, Connecticut, USA

Abstract

Abstract We report a case of multidrug-resistant Pseudomonas aeruginosa meningitis treated with ceftolozane-tazobactam with concomitant therapeutic drug monitoring of plasma and cerebral spinal fluid. The data suggest that ceftolozane-tazobactam may be an option for select central nervous system infections; however, treatment decisions should be interpreted on a case-by-case basis.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofaa549/34275049/ofaa549.pdf

Reference28 articles.

1. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents;Kadri;Clin Infect Dis,2018

2. Impact of difficult-to-treat resistance in gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data;Huh;Clin Infect Dis,2020

3. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections;Nau;Clin Microbiol Rev,2010

4. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia;Shields;Antimicrob Agents Chemother,2017

5. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial;Wunderink;Infect Dis Ther,2018

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post‐neurosurgical extensively/multidrug‐resistant Gram‐negative bacteria‐related meningitis/ventriculitis in the current era of novel beta‐lactams and beta‐lactam/beta‐lactamase inhibitor combinations?;International Journal of Antimicrobial Agents;2024-06

2. New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections;Antibiotics;2024-01-07

3. Defining International Critical Care Pharmacist Contributions to Sepsis and Exploring Variability;Current Infectious Disease Reports;2023-12-20

4. Direct Thermal Growth of Gold Nanopearls on 3D Interweaved Hydrophobic Fibers as Ultrasensitive Portable SERS Substrates for Clinical Applications;Small;2023-03-28

5. The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults;Antibiotics;2022-12-19